ALP Bio offers an integrated platform to predict, validate, and redesign therapeutic antibodies to reduce anti‑drug antibody (ADA) risk before clinical trials. Their solution combines in‑silico screening, a proprietary human tonsil organoid assay, and generative AI‑driven redesign to identify and mitigate immunogenic epitopes, helping developers avoid late‑stage failures due to ADA formation.
Funding
$2.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Anti‑drug antibody (ADA) responses frequently emerge late in biologics development, causing loss of efficacy, safety concerns, and costly program failures. The lack of early, predictive immunogenicity data forces developers to redesign or abandon candidates after significant investment.
Solution
ALP Bio offers a hybrid platform that combines human tonsil organoid assays with generative AI to predict, validate, and mitigate immunogenicity risk during antibody lead optimization. First, in‑silico screening evaluates candidate sequences against population‑scale immune response patterns to flag high‑risk epitopes. Next, the proprietary ex‑vivo tonsil organoid system reproduces human B‑ and T‑cell interactions, providing experimental ADA readouts across diverse patient populations. Finally, flagged epitopes are redesign‑ed using AI‑driven generative models that preserve target binding while reducing immunogenic potential. The iterative “predict‑validate‑re‑engineer” loop enables developers to de‑risk programs before entering clinical trials, improving candidate selection and reducing downstream attrition.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing therapeutic antibodies who need early immunogenicity intelligence to guide lead selection and optimization.
Features
- In‑silico ADA risk assessment using machine‑learning models trained on large immune response datasets
- Human tonsil organoid assay that captures authentic B‑cell, T‑cell, and antigen‑presenting cell interactions at scale
- Generative AI design engine that proposes sequence modifications to eliminate immunogenic epitopes while maintaining functional activity
- Integrated workflow that links computational predictions, ex‑vivo validation, and AI‑guided redesign in a single platform
- Population‑level readouts that enable risk stratification across diverse patient cohorts
- Automated data pipeline for rapid iteration and quantitative reporting of immunogenicity metrics